Fig. 5
Binding of sulfatide-expressing (a) MDA.SUL cells and (b) MDA.C cells to P-selectin-expressing CHO-Pro-5 (CHO-Pro5/SELP) cells or E-selectin-expressing CHO-Pro-5 (CHO-Pro5/ELAM) cells and control CHO-Pro-5 cells under defined laminar flow conditions. Points on graphs represent mean numbers of breast cancer cells interacting with CHO-Pro-5 cells obtained from three independent experiments. Formation of heterotypic tumour cell–platelet aggregates by breast cancer MDA-MB-231 cells and activated platelets. Turbidimetric platelet aggregation assay with activated platelets and MDA-MB-231, MDA.C and MDA.SUL cells. Platelets (106) and tumour cells (106) in 1 ml of Tyrode’s buffer incubated in absence (c) or presence of 1 μM (d) or 5 μM ADP (e). ADP adensoine diphosphate, PPP platelet-poor plasma, PRP platelet-rich plasma